Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse the immune evasion effect of STK11 loss-of-function mutations. The company has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Tango Therapeutics Inc.

There’s no shortage of investing strategies, but growth investing remains one of the most popular approaches. Stocks that climb 50%, 100%, or more ...

2 Monster Growth Stocks Analysts Think Can Reach New Highs

Tango Therapeutics ( ($TNGX) ) just unveiled an update. On June 19, 2026, Tango Therapeutics expanded its board to seven members and appointed biop...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TNGX	$30.08	+1.45%	830.40K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TNGX	$30.08	+1.5%	830.40K
3
4
5
6

TNGX

TNGX

Get Tango Therapeutics Inc. Data in Excel

Get Tango Therapeutics Inc. Data in Excel